Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 04/25 10:00:01 pm
174.83 USD   +1.68%
04/25AMGEN : beats Street, tweaks guidance
AQ
04/25Amgen considering risk-based Aimovig pricing
AQ
04/24AMGEN : 1Q Earnings Snapshot
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 10:40pm CEST

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
04/25AMGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
04/25AMGEN : beats Street, tweaks guidance
AQ
04/25Amgen considering risk-based Aimovig pricing
AQ
04/24AMGEN : 1Q Earnings Snapshot
AQ
04/24AMGEN INC : Results of Operations and Financial Condition, Financial Statements ..
AQ
04/24AMGEN : Reports First Quarter 2018 Financial Results
PR
04/24Women's Health Market Analysis on Segment, Trend, Growth, Volume, Size, Globa..
AQ
04/20AMGEN : Novartis presents first-of-its-kind evidence at AAN reinforcing robust a..
AQ
04/19AMGEN : Announces Webcast Of 2018 First Quarter Financial Results
PR
04/19AMGEN : To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluatin..
AQ
More news
News from SeekingAlpha
04/25Amgen Inc. 2018 Q1 - Results - Earnings Call Slides 
04/25AbbVie files U.S. marketing application for plaque psoriasis med risankizumab 
04/25Facebook Steps Up To The Earnings Plate, Comcast Bids For Sky (Wall Street Br.. 
04/25WALL STREET BREAKFAST : Facebook Back In The Spotlight 
04/25Mr. Market Grasps The Esoteric 
Financials ($)
Sales 2018 22 674 M
EBIT 2018 11 452 M
Net income 2018 8 330 M
Finance 2018 8 641 M
Yield 2018 2,96%
P/E ratio 2018 14,42
P/E ratio 2019 13,31
EV / Sales 2018 4,77x
EV / Sales 2019 4,63x
Capitalization 117 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 195 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
John Tsai Chief Medical Officer & SVP-Global Medical
Frank C. Herringer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN0.44%116 720
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.60%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
MERCK AND COMPANY6.79%162 398